Elcelyx Therapeutics

Elcelyx Therapeutics was founded in 2010 and is backed by venture capital based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary first-in-class gut sensory modulators are delivered directly to the lower gastrointestinal tract, where they act on molecular targets to trigger physiological and pharmacological effects. Elcelyx’s proprietary product candidate, NewMet, for type 2 diabetes, is entering Phase 2b development, representing a significant opportunity to address unmet needs in the oral antidiabetic market. Elcelyx is led by an experienced management team and board of directors with a successful track record in drug development and commercialization. The team is supported by senior investors as well as experienced scientists and clinicians. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc., an independent company focused on the development of non-NewMet assets. Elcelyx is headquartered in San Diego, California.